U.S. SEC files suit over possible insider trading on Bioverativ

(Reuters) - The U.S. Securities and Exchange Commission filed an insider trading lawsuit on Friday against "unknown traders" who it said engaged in "highly suspicious trading" just ahead of the announcement that hemophilia specialist Bioverativ Inc had agreed to be acquired by France's Sanofi in an $11.6 billion deal.